Chemotherapy in patients with recurrent and progressive central neurocytoma

Alba A. Brandes, Pietro Amistà, Marina Gardiman, Lorenzo Volpin, Daniela Danieli, Bianca Guglielmi, Carla Carollo, Gianpietro Pinna, Sergio Turazzi, Silvio Monfardini

Research output: Contribution to journalArticle

Abstract

BACKGROUND. Recurrent central neurocytoma is very rare and to the authors' knowledge data regarding its response to chemotherapy currently are not available. METHODS. Three patients with progressive neurocytoma received chemotherapy after their informed consent was obtained. Disease recurred in two patients after surgery and radiotherapy and in one patient after surgery. The treatment regimen was comprised of etoposide, 40 mg/m2/day, for 4 days; cisplatin, 25 mg/m2/day, for 4 days; and cyclophosphamide, 1000 mg/m2, on Day 4; this cycle was repeated every 4 weeks. RESULTS. Stabilization of disease was observed in 2 patients and complete remission was observed in 1 patient; at last follow-up, these responses had been maintained for 15 months, 18 months, and 36 months, respectively. CONCLUSIONS. In this small series, this therapeutic regimen led to long term disease reduction, and merits further study.

Original languageEnglish
Pages (from-to)169-174
Number of pages6
JournalCancer
Volume88
Issue number1
DOIs
Publication statusPublished - Jan 1 2000

Fingerprint

Neurocytoma
Drug Therapy
Etoposide
Informed Consent
Cyclophosphamide
Cisplatin
Radiotherapy
Therapeutics

Keywords

  • Central neurocytoma
  • Chemotherapy
  • Recurrent
  • Review

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Brandes, A. A., Amistà, P., Gardiman, M., Volpin, L., Danieli, D., Guglielmi, B., ... Monfardini, S. (2000). Chemotherapy in patients with recurrent and progressive central neurocytoma. Cancer, 88(1), 169-174. https://doi.org/10.1002/(SICI)1097-0142(20000101)88:1<169::AID-CNCR23>3.0.CO;2-7

Chemotherapy in patients with recurrent and progressive central neurocytoma. / Brandes, Alba A.; Amistà, Pietro; Gardiman, Marina; Volpin, Lorenzo; Danieli, Daniela; Guglielmi, Bianca; Carollo, Carla; Pinna, Gianpietro; Turazzi, Sergio; Monfardini, Silvio.

In: Cancer, Vol. 88, No. 1, 01.01.2000, p. 169-174.

Research output: Contribution to journalArticle

Brandes, AA, Amistà, P, Gardiman, M, Volpin, L, Danieli, D, Guglielmi, B, Carollo, C, Pinna, G, Turazzi, S & Monfardini, S 2000, 'Chemotherapy in patients with recurrent and progressive central neurocytoma', Cancer, vol. 88, no. 1, pp. 169-174. https://doi.org/10.1002/(SICI)1097-0142(20000101)88:1<169::AID-CNCR23>3.0.CO;2-7
Brandes, Alba A. ; Amistà, Pietro ; Gardiman, Marina ; Volpin, Lorenzo ; Danieli, Daniela ; Guglielmi, Bianca ; Carollo, Carla ; Pinna, Gianpietro ; Turazzi, Sergio ; Monfardini, Silvio. / Chemotherapy in patients with recurrent and progressive central neurocytoma. In: Cancer. 2000 ; Vol. 88, No. 1. pp. 169-174.
@article{09cacbfbc654474f999300bd5cea8048,
title = "Chemotherapy in patients with recurrent and progressive central neurocytoma",
abstract = "BACKGROUND. Recurrent central neurocytoma is very rare and to the authors' knowledge data regarding its response to chemotherapy currently are not available. METHODS. Three patients with progressive neurocytoma received chemotherapy after their informed consent was obtained. Disease recurred in two patients after surgery and radiotherapy and in one patient after surgery. The treatment regimen was comprised of etoposide, 40 mg/m2/day, for 4 days; cisplatin, 25 mg/m2/day, for 4 days; and cyclophosphamide, 1000 mg/m2, on Day 4; this cycle was repeated every 4 weeks. RESULTS. Stabilization of disease was observed in 2 patients and complete remission was observed in 1 patient; at last follow-up, these responses had been maintained for 15 months, 18 months, and 36 months, respectively. CONCLUSIONS. In this small series, this therapeutic regimen led to long term disease reduction, and merits further study.",
keywords = "Central neurocytoma, Chemotherapy, Recurrent, Review",
author = "Brandes, {Alba A.} and Pietro Amist{\`a} and Marina Gardiman and Lorenzo Volpin and Daniela Danieli and Bianca Guglielmi and Carla Carollo and Gianpietro Pinna and Sergio Turazzi and Silvio Monfardini",
year = "2000",
month = "1",
day = "1",
doi = "10.1002/(SICI)1097-0142(20000101)88:1<169::AID-CNCR23>3.0.CO;2-7",
language = "English",
volume = "88",
pages = "169--174",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Chemotherapy in patients with recurrent and progressive central neurocytoma

AU - Brandes, Alba A.

AU - Amistà, Pietro

AU - Gardiman, Marina

AU - Volpin, Lorenzo

AU - Danieli, Daniela

AU - Guglielmi, Bianca

AU - Carollo, Carla

AU - Pinna, Gianpietro

AU - Turazzi, Sergio

AU - Monfardini, Silvio

PY - 2000/1/1

Y1 - 2000/1/1

N2 - BACKGROUND. Recurrent central neurocytoma is very rare and to the authors' knowledge data regarding its response to chemotherapy currently are not available. METHODS. Three patients with progressive neurocytoma received chemotherapy after their informed consent was obtained. Disease recurred in two patients after surgery and radiotherapy and in one patient after surgery. The treatment regimen was comprised of etoposide, 40 mg/m2/day, for 4 days; cisplatin, 25 mg/m2/day, for 4 days; and cyclophosphamide, 1000 mg/m2, on Day 4; this cycle was repeated every 4 weeks. RESULTS. Stabilization of disease was observed in 2 patients and complete remission was observed in 1 patient; at last follow-up, these responses had been maintained for 15 months, 18 months, and 36 months, respectively. CONCLUSIONS. In this small series, this therapeutic regimen led to long term disease reduction, and merits further study.

AB - BACKGROUND. Recurrent central neurocytoma is very rare and to the authors' knowledge data regarding its response to chemotherapy currently are not available. METHODS. Three patients with progressive neurocytoma received chemotherapy after their informed consent was obtained. Disease recurred in two patients after surgery and radiotherapy and in one patient after surgery. The treatment regimen was comprised of etoposide, 40 mg/m2/day, for 4 days; cisplatin, 25 mg/m2/day, for 4 days; and cyclophosphamide, 1000 mg/m2, on Day 4; this cycle was repeated every 4 weeks. RESULTS. Stabilization of disease was observed in 2 patients and complete remission was observed in 1 patient; at last follow-up, these responses had been maintained for 15 months, 18 months, and 36 months, respectively. CONCLUSIONS. In this small series, this therapeutic regimen led to long term disease reduction, and merits further study.

KW - Central neurocytoma

KW - Chemotherapy

KW - Recurrent

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=0033970860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033970860&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(20000101)88:1<169::AID-CNCR23>3.0.CO;2-7

DO - 10.1002/(SICI)1097-0142(20000101)88:1<169::AID-CNCR23>3.0.CO;2-7

M3 - Article

C2 - 10618620

AN - SCOPUS:0033970860

VL - 88

SP - 169

EP - 174

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -